Matti Sällberg

Matti Sällberg is a Professor in Biomedical Analysis at Karolinska Institutet's Department of Laboratory Medicine, leading the VIVAC research group focused on vaccines and immunotherapies against viruses and cancer. He earned his DDS and PhD from Karolinska Institutet (1988-1992), followed by postdoctoral research at The Scripps Research Institute (1994-1996). As a leader in infectious disease and hepatology, his research addresses chronic viral hepatitis, cancer prevention, and gene/cell-based therapies (GTMPs/ATMPs). He has directed the Department of Laboratory Medicine (2011-2022) and actively teaches in biomedical laboratory science, dentistry, medicine, and nursing programs.

Key research areas include SARS-CoV-2 vaccine development (OPENCORONA consortium), hepatitis B/D/C therapies, and Crimean-Congo hemorrhagic fever vaccines. His work combines basic science with translational efforts at Karolinska's ANA Futura facility. Notable projects include a phase I clinical trial for a broad-acting SARS-CoV vaccine and preclinical testing of hepatitis therapies. Collaborations span academia and industry, with funding from the Swedish Cancer Society, EU, and VINNOVA. He oversees advanced techniques like viral propagation, flow cytometry, and adoptive cell therapy manufacturing.

Grants include a 2024 Swedish Cancer Society award for hepatitis-related cancer therapies and a 2022 Swedish Research Council grant for the Doctoral Program in Advanced Therapies. His team maintains an active lab with researchers like Lars Frelin and Gustaf Ahlén. Future work emphasizes expanding vaccine platforms against emerging pathogens and optimizing immuno-therapies for solid tumors.